IRS-1 G972R基因多态性对人内皮功能以及炎症状态的影响及其机制研究
|
摘要
目的：研究湖南长株潭地区汉族人群中IRS-1Gly972Arg基因多态性与原发性高血压、胰岛素抵抗与内皮功能受损相互之间作用的关系。
研究方法：选取湖南省长株潭地区510名经确诊的原发性高血压和胰岛素抵抗患者及520名健康对照者。其中单纯高血压患者184例,单纯胰岛素抵抗患者178例,高血压合并胰岛素抵抗患者145例,均为汉族人群。健康对照组选自于高血压或胰岛素抵抗患者同一地区的无血缘关系的群体,无高血压、糖尿病病史及家族史(计520例,其中男性271例,女性249例)。测量对象一般指标(如BMI、腰臀比、血压、血糖、血脂、肝肾功能等),并进行口服葡萄糖耐量试验(OGTT)评估受试者的胰岛素抵抗情况,使用HP Sonos5500彩色超声系统检测受试者肱动脉介导的血管舒张水平(FMD)。应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,对受试者IRS-1Gly972Arg基因多态性进行基因分型。
结果：IRS-1Gly972Arg基因多态性符合Hardy-Weinberg平衡定律。IRS-1基因Gly972Arg多态性的突变率(即G/A基因型频率)：原发性高血压患者中发现9例突变携带者(9/329),占2.7%,血压正常受试者中发现10例突变携带者(10/701),占1.4%；胰岛素抵抗患者中发现7例突变携带者(10/326),占2.1%,正常糖耐量受试者中发现12名突变携带者(12/704),占1.7%。尽管高血压组该基因突变率略高于血压正常组,胰岛素抵抗组略高于糖耐量正常组,但差异没有统计学意义。Logistic回归分析显示,经基因分型、胰岛素抵抗指数、高血压分级、吸烟、饮酒、年龄、性别、高血压家族史、血脂水平调整后,只有原发性高血压分级水平才是内皮功能受损的独立危险因素IRS-1Gly972Arg基因多态性、胰岛素抵抗以及两者之间的交互作用与内皮功能受损无明显相关性。
结论：高血压水平分级是内皮功能受损的独立危险因素,胰岛素抵抗、IRS-1Gly972Arg基因多态性,以及两者之间的交互作用与内皮功能受损无明显相关性。
目的：初步探讨IRS-1G972R变异致人群血管内皮功能受损的机制。
方法：应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,对受试者IRS-1Gly972Arg基因多态性进行基因分型。使用HP Sonos5500彩色超声系统检测受试者肱动脉介导的血管舒张水平(FMD)。ELISA法测定血清ET-1, eNos, IL-8和ICAM-1水平。外周血单个核细胞CXCR2mRNA表达水平通过Real-time PCR测定。数据进行多因素方差分析。
结果：在1030例受试者中,G972R IRS-1等位基因突变频率为11.1%。IRS-1G972R基因多态性与内皮功能受损之间无明显的统计学差异。内皮功能受损与高血压及血浆ET-1/eNOS水平明显相关。然而,在高血压受试者中,G972R IRS-1突变者其血浆ET-1/eNOS水平显著高于Gly/Gly纯合子携带者。在胰岛素抵抗的受试对象中,与Gly/Gly纯合子携带者相比,G972R IRS-1突变者血清IL-8和ICAM-1水平和单核细胞CXCR2mRNA表达水平显著升高。
结论：本研究显示,内皮功能受损的主效应因素是高血压,而不是IRS-1G972R多态性。然而,在高血压的受试者中,G972R IRS-1突变进一步增加了血清ET-1/eNOS水平, ET-1/eNOS水平与内皮功能状态密切相关；同时,在胰岛素抵抗的受试者中,G972R IRS-1突变促进了炎症反应,而炎症反应是内皮功能受损的另一个重要因素。总之,本研究结果显示,在内皮功能受损的进展中,IRS-1G972R突变与高血压之间存在交互作用；在炎症反应中,IRS-1G972R突变与胰岛素抵抗之间存在交互作用。
目的：探讨IRS-1Gly972Arg基因多态性对于高血压或胰岛素抵抗受试者采用卡托普利和罗格列酮治疗后相关指标变化值的影响。
方法：随机选取HBP,IR,HBP+IR和正常组各20例,每组按G/A基因型不同各分配10例。合并高血压组40名受试对象口服卡托普利,疗程一个月,每日25mg,比较治疗前后ET-1/eNOS表达水平变化；血浆合并胰岛素抵抗者口服罗格列酮,疗程2个月,每日4mg,比较治疗前后PBMC CXCR2mRNA表达水平变化。
结果：服用卡托普利1月后各小组的ET-1/eNOS表达水平较未服药前降低,治疗前后ET-1/eNOS变化的绝对值水平在A等位基因受试人群中高于G等位基因的受试者。但对卡托普利降低其外周血浆ET-1/eNOs表达水平的效果采用协方差分析并未得出统计学意义。协方差分析还提示,是否合并胰岛素抵抗以及等位基因类型对高血压受试者卡托普利服用后FMD升高幅度影响不显著。服用罗格列酮2个月后各小组PBMC CXCR2mRNA表达水平较未服药前均下降,但协方差分析亦未得出罗格列酮对PBMC CXCR2mRNA表达水平影响的统计学意义；此外,是否合并高血压以及等位基因类型对胰岛素抵抗受试者服用罗格列酮后PBMC CXCR2mRNA表达水平降低幅度的影响并不显著。
结论：在湖南省长株潭地区的汉族人群中,服用卡托普利能有效降低高血压受试者的ET-1/eNOs表达水平,并有效改善其内皮功能；是否合并胰岛素抵抗以及IRS-1Gly972Arg基因分型并不会影响ET-1/eNOs表达水平的下降程度。服用罗格列酮后胰岛素抵抗受试者的PBMC CXCR2mRNA表达水平显著下降,但受试者是否合并高血压以及IRS-1Gly972Arg等位基因分型对其下降幅度的影响无统计学意义。
Objective:To investigate the interrelationship between IRS-1gene Gly972Arg polymorphism and primary hypertension,insulin resistance and endothelial dysfunction in Han people from Changsha,Zhuzhou and Xiangtan district.HuNan province.
Methods:184hypertensive patients,178insulin-resistant patients,145hypertensive and insulin-resistant patients and520healthy controll people were recruited from Changsha,Zhuzhou and Xiangtan district.HuNan province. BMI, WHR, BP,BS; blood fat, hepatic and renal function were measured,insulin resistant state were assessed by OGTT. FMD were determined through HP Sonos5500color ultrasound system, IRS-1gene Gly972Arg polymorphism were detected by PCR-RFLP.
Results:IRS-1gene Gly972Arg polymorphism coincide with Hardy-Weinberg equilibrium law. G/A allelic frequency:9heterogeneic carriers were detected from329hypertensive patients(2.7%),10were detected from701normotensive patients(1.4%);7were found in326insulin-resistant patients(2.1%),12were found in704subjects without insulin resistance(1.7%).Statistical difference can neither be found between hypertensive group and normotensive group nor between insulin-reisistant group and subjects without insulin resistance. Logistic regression analysis demonstrate that only hypertensive degree serves as independent risk factor of endothelial dysfunction (OR=1.983,95%CI1.215-2.573, P=0.028). No statistical relationship had been found between endothelial dysfunction and IRS-1Gly972Arg polymorphism,insulin resistance,nor the interaction between IRS-1Gly972Arg polymorphism&insulin resistance.
Conclusion:Hypertensive degree serves as independent risk factor of endothelial dysfunction. No statistical relationship had been found between endothelial dysfunction and IRS-1Gly972Arg polymorphism,insulin resistance,nor the interaction between IRS-1Gly972Arg polymorphism&insulin resistance.
Objective:To investigate a potential interrelationship between HBP、IRS-1G972R polymorphism、insulin-resistance and even FMD in vivo.
Methods:a eight cohorts of10Gly/Gly carriers without HBP or IR,10Gly/Gly carriers with HBP but without insulin resistance,10Gly/Gly carriers with insulin resistance but without HBP、10Gly/Gly carriers with HBP and insulin resistance,10heterozygous carriers without HBP or insulin resistance,10heterozygous carriers with HBP but without insulin resistance,10heterozygous carriers with insulin resistance but without HBP、10heterozygous carriers with HBP and insulin resistance were enrolled respectively. The study population were Han people from Hunan Province,China.IRS-1polymorphism was detected by PCR.Endothelium-dependent vasodilution in terms of FMD were assessed by noninvasive color ultrasound system. ET-1、eNos and IL-8, ICAM-1were determined by enzyme linked immunosorbent assay,while the expression of mononuclearcell CXCR2mRNA were measured by Real-time PCR.
Results:Allelic mutation frequency of G972R IRS-1allele were11.1%.No statistical difference were found between IRS-1G972R polymorphism and endothelial dysfunction. Statistical interrelationship lies between endothelial dysfunction and hypertension or plasma ET-1/eNOS level.However,the plasma ET-1/eNOS level of G972R IRS-1variants is statistically higher than that of Gly/Gly carriers,as detected in hypertensive subjects. Plasma IL-8and ICAM-1,as well as PBMC CXCR2mRNA elevated in G972R IRS-1variants compared with Gly/Gly carriers,as detected in insulin-resistant subjects.
Conclusion:Through inflammation as well as interaction with HBP, IRS-1G972R polymorphism contribute to impaired FMD, indirectly, and hence cardiovascular disease.
OBJECTIVE:To investigate the effects of IRS-1Gly972Arg polymorphism on hypertensive or insulin-resistant subjects treated by captopril or rosiglitazone.
Methods:20hypertensive patients,20insulin-resistant patients,20hypertensive and insulin-resistant group and20healthy controll subjects were enrolled randomly as4groups.Each group was subdivided according to G/A genotype.40hypertensive subjects had25mg captopril daily for oral use for1month, the alleosis of plasma of ET-1/eNOS between pre-and post-captopril treatment were analyzed by
statistics.40insulin-resistant subjects had4mg rosiglitazone daily for oral use for2month, the change of PBMC CXCR2mRNA between pre-and post-rosiglitazone treatmentwere also compared through covariance analysis.
Results:ET-1/eNOS level decreased after1month of captopril treatment,but no statistical difference was made in the effects of captopril on plasmaET-1/eNOs level,as demonstrated by covariance analysis.Also, covariance analysis showed that insulin resistance and allele had no statistical influence on effects of captopril on FMD elevation. PBMC CXCR2mRNA level declined after2months of rosiglitazone adminstration,but no statistical difference was made in the effect of rosiglitazone on PBMC CXCR2mRNA expression; In addition, covariance analysis revealled that hypertension and allele had no statistical contribution on effects of rosiglitazone on PBMC CXCR2mRNA degression.
Conclusion:Captopril adminstration could decrease plasma ET-1/eNOs level of hypertensive subjects and improve endothelial function;Insulin resistance and IRS-1Gly972Arg polymorphism had no influence on the effect of captopril on depressing plasmaET-1/eNOs level. Rosiglitazone adminstration may downregulate PBMC CXCR2mRNA in insulin-resistant subjects,but neither hypertension nor IRS-1Gly972Arg allele showed statistical contribution on the effects of rosiglitazone on PBMC CXCR2mRNA degression.
研究方法：选取湖南省长株潭地区510名经确诊的原发性高血压和胰岛素抵抗患者及520名健康对照者。其中单纯高血压患者184例,单纯胰岛素抵抗患者178例,高血压合并胰岛素抵抗患者145例,均为汉族人群。健康对照组选自于高血压或胰岛素抵抗患者同一地区的无血缘关系的群体,无高血压、糖尿病病史及家族史(计520例,其中男性271例,女性249例)。测量对象一般指标(如BMI、腰臀比、血压、血糖、血脂、肝肾功能等),并进行口服葡萄糖耐量试验(OGTT)评估受试者的胰岛素抵抗情况,使用HP Sonos5500彩色超声系统检测受试者肱动脉介导的血管舒张水平(FMD)。应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,对受试者IRS-1Gly972Arg基因多态性进行基因分型。
结果：IRS-1Gly972Arg基因多态性符合Hardy-Weinberg平衡定律。IRS-1基因Gly972Arg多态性的突变率(即G/A基因型频率)：原发性高血压患者中发现9例突变携带者(9/329),占2.7%,血压正常受试者中发现10例突变携带者(10/701),占1.4%；胰岛素抵抗患者中发现7例突变携带者(10/326),占2.1%,正常糖耐量受试者中发现12名突变携带者(12/704),占1.7%。尽管高血压组该基因突变率略高于血压正常组,胰岛素抵抗组略高于糖耐量正常组,但差异没有统计学意义。Logistic回归分析显示,经基因分型、胰岛素抵抗指数、高血压分级、吸烟、饮酒、年龄、性别、高血压家族史、血脂水平调整后,只有原发性高血压分级水平才是内皮功能受损的独立危险因素IRS-1Gly972Arg基因多态性、胰岛素抵抗以及两者之间的交互作用与内皮功能受损无明显相关性。
结论：高血压水平分级是内皮功能受损的独立危险因素,胰岛素抵抗、IRS-1Gly972Arg基因多态性,以及两者之间的交互作用与内皮功能受损无明显相关性。
目的：初步探讨IRS-1G972R变异致人群血管内皮功能受损的机制。
方法：应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,对受试者IRS-1Gly972Arg基因多态性进行基因分型。使用HP Sonos5500彩色超声系统检测受试者肱动脉介导的血管舒张水平(FMD)。ELISA法测定血清ET-1, eNos, IL-8和ICAM-1水平。外周血单个核细胞CXCR2mRNA表达水平通过Real-time PCR测定。数据进行多因素方差分析。
结果：在1030例受试者中,G972R IRS-1等位基因突变频率为11.1%。IRS-1G972R基因多态性与内皮功能受损之间无明显的统计学差异。内皮功能受损与高血压及血浆ET-1/eNOS水平明显相关。然而,在高血压受试者中,G972R IRS-1突变者其血浆ET-1/eNOS水平显著高于Gly/Gly纯合子携带者。在胰岛素抵抗的受试对象中,与Gly/Gly纯合子携带者相比,G972R IRS-1突变者血清IL-8和ICAM-1水平和单核细胞CXCR2mRNA表达水平显著升高。
结论：本研究显示,内皮功能受损的主效应因素是高血压,而不是IRS-1G972R多态性。然而,在高血压的受试者中,G972R IRS-1突变进一步增加了血清ET-1/eNOS水平, ET-1/eNOS水平与内皮功能状态密切相关；同时,在胰岛素抵抗的受试者中,G972R IRS-1突变促进了炎症反应,而炎症反应是内皮功能受损的另一个重要因素。总之,本研究结果显示,在内皮功能受损的进展中,IRS-1G972R突变与高血压之间存在交互作用；在炎症反应中,IRS-1G972R突变与胰岛素抵抗之间存在交互作用。
目的：探讨IRS-1Gly972Arg基因多态性对于高血压或胰岛素抵抗受试者采用卡托普利和罗格列酮治疗后相关指标变化值的影响。
方法：随机选取HBP,IR,HBP+IR和正常组各20例,每组按G/A基因型不同各分配10例。合并高血压组40名受试对象口服卡托普利,疗程一个月,每日25mg,比较治疗前后ET-1/eNOS表达水平变化；血浆合并胰岛素抵抗者口服罗格列酮,疗程2个月,每日4mg,比较治疗前后PBMC CXCR2mRNA表达水平变化。
结果：服用卡托普利1月后各小组的ET-1/eNOS表达水平较未服药前降低,治疗前后ET-1/eNOS变化的绝对值水平在A等位基因受试人群中高于G等位基因的受试者。但对卡托普利降低其外周血浆ET-1/eNOs表达水平的效果采用协方差分析并未得出统计学意义。协方差分析还提示,是否合并胰岛素抵抗以及等位基因类型对高血压受试者卡托普利服用后FMD升高幅度影响不显著。服用罗格列酮2个月后各小组PBMC CXCR2mRNA表达水平较未服药前均下降,但协方差分析亦未得出罗格列酮对PBMC CXCR2mRNA表达水平影响的统计学意义；此外,是否合并高血压以及等位基因类型对胰岛素抵抗受试者服用罗格列酮后PBMC CXCR2mRNA表达水平降低幅度的影响并不显著。
结论：在湖南省长株潭地区的汉族人群中,服用卡托普利能有效降低高血压受试者的ET-1/eNOs表达水平,并有效改善其内皮功能；是否合并胰岛素抵抗以及IRS-1Gly972Arg基因分型并不会影响ET-1/eNOs表达水平的下降程度。服用罗格列酮后胰岛素抵抗受试者的PBMC CXCR2mRNA表达水平显著下降,但受试者是否合并高血压以及IRS-1Gly972Arg等位基因分型对其下降幅度的影响无统计学意义。
Objective:To investigate the interrelationship between IRS-1gene Gly972Arg polymorphism and primary hypertension,insulin resistance and endothelial dysfunction in Han people from Changsha,Zhuzhou and Xiangtan district.HuNan province.
Methods:184hypertensive patients,178insulin-resistant patients,145hypertensive and insulin-resistant patients and520healthy controll people were recruited from Changsha,Zhuzhou and Xiangtan district.HuNan province. BMI, WHR, BP,BS; blood fat, hepatic and renal function were measured,insulin resistant state were assessed by OGTT. FMD were determined through HP Sonos5500color ultrasound system, IRS-1gene Gly972Arg polymorphism were detected by PCR-RFLP.
Results:IRS-1gene Gly972Arg polymorphism coincide with Hardy-Weinberg equilibrium law. G/A allelic frequency:9heterogeneic carriers were detected from329hypertensive patients(2.7%),10were detected from701normotensive patients(1.4%);7were found in326insulin-resistant patients(2.1%),12were found in704subjects without insulin resistance(1.7%).Statistical difference can neither be found between hypertensive group and normotensive group nor between insulin-reisistant group and subjects without insulin resistance. Logistic regression analysis demonstrate that only hypertensive degree serves as independent risk factor of endothelial dysfunction (OR=1.983,95%CI1.215-2.573, P=0.028). No statistical relationship had been found between endothelial dysfunction and IRS-1Gly972Arg polymorphism,insulin resistance,nor the interaction between IRS-1Gly972Arg polymorphism&insulin resistance.
Conclusion:Hypertensive degree serves as independent risk factor of endothelial dysfunction. No statistical relationship had been found between endothelial dysfunction and IRS-1Gly972Arg polymorphism,insulin resistance,nor the interaction between IRS-1Gly972Arg polymorphism&insulin resistance.
Objective:To investigate a potential interrelationship between HBP、IRS-1G972R polymorphism、insulin-resistance and even FMD in vivo.
Methods:a eight cohorts of10Gly/Gly carriers without HBP or IR,10Gly/Gly carriers with HBP but without insulin resistance,10Gly/Gly carriers with insulin resistance but without HBP、10Gly/Gly carriers with HBP and insulin resistance,10heterozygous carriers without HBP or insulin resistance,10heterozygous carriers with HBP but without insulin resistance,10heterozygous carriers with insulin resistance but without HBP、10heterozygous carriers with HBP and insulin resistance were enrolled respectively. The study population were Han people from Hunan Province,China.IRS-1polymorphism was detected by PCR.Endothelium-dependent vasodilution in terms of FMD were assessed by noninvasive color ultrasound system. ET-1、eNos and IL-8, ICAM-1were determined by enzyme linked immunosorbent assay,while the expression of mononuclearcell CXCR2mRNA were measured by Real-time PCR.
Results:Allelic mutation frequency of G972R IRS-1allele were11.1%.No statistical difference were found between IRS-1G972R polymorphism and endothelial dysfunction. Statistical interrelationship lies between endothelial dysfunction and hypertension or plasma ET-1/eNOS level.However,the plasma ET-1/eNOS level of G972R IRS-1variants is statistically higher than that of Gly/Gly carriers,as detected in hypertensive subjects. Plasma IL-8and ICAM-1,as well as PBMC CXCR2mRNA elevated in G972R IRS-1variants compared with Gly/Gly carriers,as detected in insulin-resistant subjects.
Conclusion:Through inflammation as well as interaction with HBP, IRS-1G972R polymorphism contribute to impaired FMD, indirectly, and hence cardiovascular disease.
OBJECTIVE:To investigate the effects of IRS-1Gly972Arg polymorphism on hypertensive or insulin-resistant subjects treated by captopril or rosiglitazone.
Methods:20hypertensive patients,20insulin-resistant patients,20hypertensive and insulin-resistant group and20healthy controll subjects were enrolled randomly as4groups.Each group was subdivided according to G/A genotype.40hypertensive subjects had25mg captopril daily for oral use for1month, the alleosis of plasma of ET-1/eNOS between pre-and post-captopril treatment were analyzed by
statistics.40insulin-resistant subjects had4mg rosiglitazone daily for oral use for2month, the change of PBMC CXCR2mRNA between pre-and post-rosiglitazone treatmentwere also compared through covariance analysis.
Results:ET-1/eNOS level decreased after1month of captopril treatment,but no statistical difference was made in the effects of captopril on plasmaET-1/eNOs level,as demonstrated by covariance analysis.Also, covariance analysis showed that insulin resistance and allele had no statistical influence on effects of captopril on FMD elevation. PBMC CXCR2mRNA level declined after2months of rosiglitazone adminstration,but no statistical difference was made in the effect of rosiglitazone on PBMC CXCR2mRNA expression; In addition, covariance analysis revealled that hypertension and allele had no statistical contribution on effects of rosiglitazone on PBMC CXCR2mRNA degression.
Conclusion:Captopril adminstration could decrease plasma ET-1/eNOs level of hypertensive subjects and improve endothelial function;Insulin resistance and IRS-1Gly972Arg polymorphism had no influence on the effect of captopril on depressing plasmaET-1/eNOs level. Rosiglitazone adminstration may downregulate PBMC CXCR2mRNA in insulin-resistant subjects,but neither hypertension nor IRS-1Gly972Arg allele showed statistical contribution on the effects of rosiglitazone on PBMC CXCR2mRNA degression.
引文
[1]Mather K,Anderson TJ,Verma S.Insulin Action in the Vasculature:Physiology and Pathophysiology J Vase Res 2001,38(5)415-422.
[2]Hsueh WA,Quinones MJ.Role of Endothelial Dysfunctioon in Insulin Resistance.Am J Cardiol.2003,92(4A):10J-17J
[3]Cai H,Harrison DG.Endothelial Dysfunction in Cardiovascualr Diseases:The Role of Oxidant Stress.Circ Res,2000,87(10):840-844.
[4]Suwaidi JA,Hamasaki S,Higano S,et al.Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.Circulation,2000,101:948-954.
[5]Laakso M.Insulin resistance and cardiovascular disease.Br J Diabetes Vase Dis.2002,2(suppl 1):S9-S11.
[6]Reaven GM.Role of insulin resistance in human disease.Diabetes.1988, 37:1598-1607
[7]Baron AD.Insulin resistance and vascular function.Journal of Diabetes and Its Complications.2002,(16):92-102.
[8]Abe H,Yamada N,Kamata K,et al.Hypertension,hypertriglyceridemia,and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1.J Chin Invest,1998;101(8):1784-1788.
[9]Baron AD.Vascular Reactivity.Am J Cardiol.1999,84(1A):25J-27J
[10]Jiang ZY,Lin Y-W,Clemont A,et al.Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker(fa/fa)rats.J Chin Invest.1999, 104(4):447-457.
[11]Katakam PV,Tulbert CD,Snipes JA,et al.Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species.Am J Physiol Heart Circ Physiol.2005,288(2):H854-H860.
[12]Myers MG,White MF.The new elements of insulin signaling.Insulin receptor substrate-1 and proteins with SH2 domain.Diebetes,1993,42:643-650.
[13]Koch CA,Anderson D,Moran MF,et al.Sh2 and Sh3 domains:elements that control interactions of cytoplasmic signaling proteins.Science,1991,252:668-674.
[14]Cusi K,Maezon K,Vsman A,et al.Insulin resistance differentially affects the PI3-kinase and MAPA kinase mediated signaling in human muscle.J Chin Inverse,2000,105:311-320.
[15]Araki E,Lipes MA,Patti ME,et al.Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene.Nature,1994:372(6502):186-190.
[16]Tamemoto H,Kadowaki T,Tove K,et al.Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1.Nature,1994;372(6502):182-186
[17]Kido Y,Burks DJ,Withers D.et al.Tissue-specific insulin resistance in mice with mutation in the insulin receptor, IRS-1,and IRS-2.J Clin Invest,2000; 105:199-205.
[18]Shirakami A,Toyonaga T,Tsuruzoe K,et al.Heterozygous knockout of the IRS-1 gene in mice enhances obesity-linked insulin resistance:a possible model for the development of type 2 diabetes.J Endocrinol,2002; 174(2):309-319.
[19]Baroni MG,Leonetti F,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene is associated with insulin resistance in "uncomplicated"obese subjects evaluated by hyperinsulinemic-euglycemic clamp.J Endocrinol Invest,2004; 27(8):754-759.
[20]Baroni MG,Arca M,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene,body fat distribution and insulin-resistance.Diabetologia,2001; 44(3):367-372.
[21]Abe H,Yamada N,Kamata K,et al.Hypertension,hypertriglyceridemia,and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1.J Chin Invest,1998;101(8):1784-1788.
[22]Sloniger JA,Saengsirisuwan V,Diehl CJ,et al.Defective insulin signaling in skeletal muscle of the hypertensive TG (mREN2) 27 rat.Am J Physiol Endocrinol Metab,2005,288 (6):E1074-1081.
[23]Perticone F,Sciacqua A,Sconzzafava A,et al.Impaired endothelial function in never-treated hypertensivve subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene.J Chin Endocrinol Metab,2004;89(7):3606-3609.
[24]Federci M,Pandolfi A,De Filippis EA,et al.G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells.Circulation,2004;109(3):399-405.
[25]Sugita H.Fujimoto M,Yasukawa T,et al.Inducible nitric-oxide synthase and NO donor induce insulin receptor subtrate-1 degradation in skeletal muscle cells.J Biol Chem,2005;280(14):14203-14211.
[26]McGettrick AJ,Feener EP,Kahn CR.Human insulin receptor substrate-1 (IRS-1 polymorphism G972R causes IRS-1 to associated with the insulin receptor and inhibit receptor autophosphorylation.J Biol Chem,2005;280(8): 6441-6446.
[27]Celermajer DS,Sorenson K, Gooch VM,et al.Non-invasive detection of endothe-lial dysfunction in Children and adults at risk of atherosclerosis[J]. Lancet,1992; 340:1111-1115.
[28]Celemajer DS,Sorensen KE,Spiegelhaleter DJ,et al.Aging is associated endothelial dysfunction in healthy man years before the agerelated decline in women[J] J Am Coll Cardiol,1994;24:471-476.
[29]邓又斌,黎春蕾,朱蔚等。冷加压试验超声心动图评价高血压患者的冠状动脉内皮功能[J].中国超声医学杂志,2000；16(6)：423-425.
[l]Cherry PD,Furchgott RF,Zawadzki JV,et al.Role of endothelial cells in relaxation of isolated arteries by bradykinin[J].Proc Natl Acad Sci USA,1982;79:2106-2110.
[2]Uedas,Matsuoka H,Miyazaki H,et al.Tetrahydrobiopterin restores endothelial function in long-term smokes[J]. J Am Coll Cardiol,2000;35 (1):71-75.
[3]李妍妍,徐标。一氧化氮与心血管疾病研究进展[J]。国外医学内科学分册,2002：29(10)：426-429.
[4]Salemo JC,Harris DE,Irizarry K, et al.An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase[J].J Biol Chem,1998; 272:29769-29777.
[5]Nishida CR,de Montellano PR.Control of election transfer in mitric-oxide synthases swapping of autoinhibitory elements among nitric-oxide synthase isoforms[J].J Biol Chem,2001;276(23):20116-20124.
[6]Teubl M,Groschner K,Kohuwein SD,et al.Na+/Ca2+ exchange facilitates Ca2+-dependent activation of endothelial nitric-oxide synthase[J].J Biol Chem, 1999;274(41):29529-29535.
[7]Buga GM,Gold ME,Fukuto JM,et al.Shear stress induced release of nitric oxide from endothelial cells trown on beads[J].Hypertens,1991;17:187-193.
[8]Rai JL,Nitric oxide and the kidney[J].Circulation,1993;87:26-29.
[9]Garcia NH,Stoos BA,Carretero OA,Garvin JL.Mechanism of the nitric oxide induced blockade of collecting duct water permeability [J]. Hypertens,1996; 270:c794-802.
[10]Granger J,Novak J,Schnackenberg C,et al.Role of renal nerves in mediationg the hypertensive effects of nitric oxide synthesis inhibitioon[J].Hypertens,1996;27 (3pt2):613-617.
[11]周泉生、阮长耿。一氧化氮及其合成酶异常与疾病[J].生理学进展,1995：26：169-171.
[12]Helmut O,Basel B,Gincer H,et al.Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans[J].Circulation,1997; 96:3287-3293.
[13]Lushcher TF.Imbalance of endothelium derived relaxing and contracting factors:A new concept in hypertensioon[J].Am J Hypertens,1990;3:317.
[14]Schiffrin EL.Potential in hypertensioon and vascular hypertrophy[J].Hypertens, 1990;25:1135-43.
[15]Amir L,John CB,Stuart TH,et al.Long-term L-arginine supple-mentation improves small vessel coronary endothelial function in humans[J].Circulation, 1998;97:2123.
[16]John M.Role of angiotensin-convention enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease [J].Am J Med,1998;105(A):405.
[17]Schiffrin EL. Vascular endothelin in hypertension [J]. Vasc Pharmacol,2005, 43 (1):19229.
[18]Johnson FK, Johnson RA, Peyton KJ, et al. Arginase inhibition restores arterio2 lar endothelial function in Dahl ratswith salt2induced hypertension [J]. Am J Physiol Regul Integr Comp Physiol,2005,288 (4):R105721062.
[19]RekhviashviliA, Tsinamdzgvrishvili B, ChkhetiaM, et al. The relationship between endothelial dysfunction and 242hour blood p ressure rhythm in patients with arterial hypertension[J]. GeorgianMed News,2008,155:13217.
[20]KlingbeilAU, John S, SchneiderMP, et al. Effect of AT1 recep tor blockade on endothelial function in essential hypertension [J]. Am J Hypertens,2003,16(2) 1232128.
[21]NitenbergA, Chemla D,Antony I. Ep icardial coronary artery constriction to cold pressor test is p redictive of cardiovascular events in hypertensive patients with angiographically normal coronary arteries and without othermajor coronary risk factor [J]. Atherosclerosis,2004,173 (1):1152123.
[22]L i LJ, Yu CM, Geng SR, et al. Endothelial dysfunction in young normotensive subjectswith a family history of essential hypertension [J]. Xi'anMed Univ,2002,14 (1):81285.
[23]Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients [J]. Circulation,2001,104 (2):1912196.
[24]ModenaMG,Bonetti L, Copp i F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women [J]. J Am Coll Cardiol,2002,40 (3):5052510.
[25]VinodMAA. Cardiovascular effects of asymmetric dimethylarginine [J]. Circu2 lation,2004,109 (25):327.
[26]TousoulisD,Antoniades C, Stefanadis C. Evaluating endothelial function in humans:a guide to invasive and noninvasive techniques [J]. Heart,2005,91 (4): 5532-5558.
[27]Shinozaki K,Ayajiki K,Nishio Y,et al.Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance.Hypertension,2004,43(2):255-262.
[28]Sowers JR.Insulin resistance and hypertension.Am J Physiol Heart Circ Physiol 2004,286(5):H1597-1602.
[29]李卫萍,孙明,周宏研,等.原发性高血压病患者血管内皮功能失调与活性氧的关系及阿托伐他汀治疗的影响[J].中国现代医学杂志,2005,15(7)1096-1103.
[30]Forman HJ,Torres M,Fukuto JlRedox signaling[J]lMol Cell Biochem,2002, 234-235(1-2):49-62
[31]Campese VM, Shaohua Y, Huiquin Z. Oxidative st ress.mediates angiotensin Ⅱ2dependent stimulation of sympathetic nerve activity. Hypertension,2005,46 (3):533
[32]Madamanchi NR,Vendrov A,Runge MS1Oxidative stress and vascular dis2 ease[J]lArterioscler Thromb Vase Biol,2005,25 (1):29-38
[33]Fernndez-Real JM,Ricart Wl Insulin resistance and chronic cardiovas2 cular inflammatory syndrome[J]Endocrine Reviews,2003,24 (3):27823011
[34]Yuan,M.,Konstantopoulos,N.,Lee,J.,Hansen,L,Li,Z.W.,Karin,M.,and Shoelson,S. E.,Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta.Science,293,1673-1677(2001).
[35]Lautenberger JA, Stephens JC, O'Brien SJ, et al. Significant admixture linkage disequilibrium across30 cM around the FYlocus in African Americans. AmJ Hum Genet.2000.66(3):969-978
[36]Araki E,Sun XJ,Haag BL 3rd,et al.Human skeletal muscle insulin receptor substrate-1.Characterization of the Cdna,gene,and chromosomal localization. Diabetes,1993;42(7):1041-1054.
[37]Almind K,Bjorbaed C,Vestergaard H,et al.Amninoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus[J].Lancet,1993, 34298875:828-832.
[38]Almind K,Inoue G,Pedersen O,et al.A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling.Evidence from transfection studies,1996;97:2569-2575.
[39]Federiei M, Pandolfi A, DeFilippis EA, et al.G972RIRS-1 variarnt impairs insulin regulation of endothelial nitrie oxide synthase in cultured human endothelial cells[J].Circulation.2004,109(3):399-405
[40]Araki E, Lipes MA, Patti ME, et al.Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene [J].Nature.1994,372(6502):186-190
[41]Tamemoto H, Kadowaki T, Tobe K, et al.Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1[J]. Nature.1994,372(6502),182-186.
[42]Kido Y,Burks DJ,Withers D,et al.Tissue-specific insulin resistance in mice with mutations in the insulin receptor,IRS-1,and IRS-2.J Chin Invest,2000; 105:199-205.
[43]Shirkami A,Toyonaga T,Tsuruzoe K,et al.Heterozygous knockout of the IRS-1 gene in mice enhances obesity-linked insulin resistance:a possible model for the development of type 2 diabetes.J Endocrinol,2002;174(2):309-319.
[44]Baroni MG,Leonetti F,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene is associated with insulin resistance in "uncomplicated" obese subjects evaluated by hyperinsulinemic-euglycemic clamp.J Endocrinol Invest,2004;27(8):754-759.
[45]Baroni MG,Arca M,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene,body fat distribution and insulin-resistance.Diabetologia,2001;44(3):367-372.
[46]Abe H,Yamada N,Kamata K,et al.Hypertension,hypertriglyceridemia,and impaired endothelium-dependent vascular relaxationin mice lacking insulin receptor substrate-1.J Chin Invest,1998;101(8):1784-1788.
[47]Francesco P,Angela Sciacqua,Angela S,et al.Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene.J.Clin.Endocrinol.Metab,2004;89:3606-3609.
[48]Baroni MG,D'Andrea MP,Montali A,Pannitteri G,Barilla F,Campagna F, Mazzei E,Lovari S,Sceeareccia F,Campa PP,Ricci G,Pazzilli P,Urbinati G,Arca M 1999 A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease.Arterioscler Thromb Vasc Biol 19:2975-2980.
[49]Ossei-Gerning N,Mansfield MW,Stickland MH,Grant PJ.Insulin receptor substrate-1 gene polymorphism and cardiovascular risk in non-insulin dependent diabetes mellitus and patients undergoing coronary angiography.Clin Lab Haema tol.1997 Jun; 19(2) 123-8.
[50]Massimo Federici,Assunta Pandolfi,Elena Anna De Filippis et al.G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells.Circulation 2004;109;399-405.
[51]Zeng G,Quon MJ.Insulin-stimulated production of nitric oxide by wortmannin.Direct measurement in vascular endothelial cells.J Chin Invest,1996,98:894-989.
[52]Potenza MA,Marasciulo FL,Chieppa DM et al.Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.American Journal of Physiology.Heart and Circulatory Physiology 2005;289(2):H813-H822。
[53]Formoso G, Chen H,Kim JA,Montagnani M,Consoli A,Quon MJ.Dehydro-epiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin-1 via distinct phosphatidylinositol 3-kinase-and mitogen-activated protein kinase-dependent pathways in vascular endothelium.Mol Endocrinol,2006,20:1153-1163.
[54]Potenza MA,Marasciulo FL,Tarquinio M,Quon MJ,Montagnani M,Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.Diabetes,2006,55:3594-3603.
[55]Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M,Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa)rats. J Clin Invest.1999; 104:447-457.
[56]Cusi K,Maezono K,Osman A,Pendergrass M,Patti ME,Pratipanawatr T,DeFronzo RA,Kahn CR,Mandarino LJ.Insulin resistance differentially affects the PI 3-kinase and MAP-kinase-mediated signaling muscle.J Chin Invest,2000,105:311-320.
[57]Juan CC,Shen YW,Chien Y,Lin YJ,Chang SF,Ho LT(2004)Insulin infusion induces endothelin-1-dependent hypertension in rats.Am J Physiol Endocrinol Metab 287:E948-E954.
[58]Shinozaki K,Ayajiki K,Nishio Y,Sugaya T,Kashiwagi A,Okamura T (2004) Evidence for a causal role of the reninangiotensin system in vascular dysfunction associated with insulin resistance.Hypertension 43:255-262.
[59]Behr-Roussel D,Oudot A,Caisey S,Coz OL,Gorny D,Bernabe J,Wayman C,Alexandre L,Giuliano FA(2008)Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance.Eur Urol53: 1272-1281.
[60]Hsueh WA,Quinones MJ.Role of endothelial dysfuction in insulin resistance.Am J.Cardiol.2003,92(4A):10J-17J
[61]Francesco P.Angela Sciacqua, Raffaele (2009)Maio.Endothelial dysfunction, ADMA and insulin resistance in essential hypertension.International J of Cardiology., 104:447-457.
[62]Arcaro QCretti A,Balzano S,Lechi A,Muggeo M,Bonora E,Bonadonna RC.Insulin causes endothelial dysfunction in humans:sites and mechanisms.Circula-tion,2002,105:576-582.
[63]邓又斌,黎春蕾,朱蔚等。冷加压试验超声心动图评价高血压患者的冠状动脉内皮功能[J].中国超声医学杂志,2000；16(6)：423-425.
[1]Yusuf S,Sleight P,Pogue J,et al.Effects of an angiotensin-converting-enzyme inhibitor,ramipril,on cardiovascular events in high-risk patients:the heart outcomes prevention evaluation study investigations[J],N Engl Med,2000,342(3):145-153.
[2]Yoshida J, Yamamoto K,Mano T, et all AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure[J]1 Hypertension,2004,43 (3):686-691
[3]Ghiadoni L,Magagna A,Versari D, et all Different effect of antihyperten-sive drugs on conduit artery endothelial function[J]1 Hypertension,2003,41 (6):1281-1286.
[4]Higashi Y,Oshima T,Sasaki S,et al.Angiotensin-converting enzyme inhitibition,but not calcium angagomism,improves a response of the renal vasculature to L-arginine in patients with essential hypertensive[J],Hypertension,1998,32:16-24.
[5]O' Driscoll G,Green D,Maiorana A,et al.Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus[J].JACC,1999,33(6):1506-1511.
[6]Shinozaki K,Ayajiki K,Nishio Y,et al.Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance.Hypertension,2004,43(2):255-262.
[7]Nyby MD,Abedi K,Smutko V,Eslami P,Tuck ML(2007)Vascular Angiotensin type 1 receptor expression is associated with vasular dysfunction,oxidative stress and inflammation in fructose-fed rats.Hypertens Res 30:451-457.
[8]Kamide K,Rakugi H,Higaki J,Okamura A,Nagia M,Moriguchi K,Ohishi M,Satoh N,Tuck ML,Ogihara (2002) The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats.Am J Hypertens 15:66-71.
[9]Uchida T,Okumura K,Ito T,Kamiya H,Nishimoto Y,Yamada M,Tomida T,Matsui H,Hayakawa T(2002)Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats.Clin Exp Pharmacol Physiol 29:381-385.
[10]Blanquart C, Barbier O, Fruchart JC, et al. Peroxisome p roliferator-activated recep tors:regulation of transcrip tional activities and roles in inflammation[J]. J Steroid BiochemMolBiol,2003,85 (225):2672273.
[11]RicoteM, Li AC, Willson TM, et al. The peroxisome p roliferator-activated recep tor2gamma is a negative regulator ofmacrophage activation[J]. Nature,1998, 391(6662):79282.
[12]Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR2gamma ligands to inhibit the ep ithelial inflammatory response [J]. J Clin Invest,1999,104 (4):3832389.
[13]Von Knethen AA, Brune B. Delayed activation of PPARgamma by LPS and IFN2gamma attenuates the oxidative burst in macrophages [J]. FASEB J,2001,15 (2):5352544.
[1]Tsuj Y,Kaburagi Y,Teranchi Y,et al.Subcellular Localization of insulin receptor Substrate Family proteins associated with phosphatidylinositol 3-kinase activity and alteration in lipolysis in primary mouse adipocytes from IRS-1 null mice[J].Diabetes,2001,50:1455-1463.
[2]Myers MG Jr,Grammer TC,Blooks J,et al/THE Plecksrin homology domain in IRS-1 sensitizes insulin signling.J Biol Chem,1995-270:11715-11718.
[3]Sun XJ,Rothenberg P,Kabncr,et al.Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein.Nature,1991,352:73-77.
[4]Araki E, Sun XJ,Hang BL,et al.Human skeletal muscle insulin receptor substrate-1,characterization of the CDNA.gene and chromosomal localization. Diabetes,1993,42:1041-1054.
[5]Nishiyama M,Wands JR.Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma.Biochem.Biophys. Res.Commun,1992,183:280-285.
[6]Myers MG,White MF.The new elements of insulin signaling.Insulin receptor substrate-1 and proteins with SH2 domain.Diebetes,1993,42:643-650.
[7]Koch CA,Anderson D,Moran MF,et al.Sh2 and Sh3 domains:elements that control interactions of cytoplasmic signaling proteins.Science,1991,252:668-674.
[8]Foll F,Saad MJ,Backer JM,et al.Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus.J Chin Inverse,1993,92:1787-1794.
[9]Lowenstein EJ,Daly RJ,Batzer AG,et al.The SH2 and SH3 domain-containing GRB2 links receptor tyrosine Kinases to ras signaling.Cell,1992,70:431-442.
[10]White MF.The insulin signaling system and the IRS proteins.Diabetoligia,1997, 40:12-17.
[11]Dhand r,Hiles I,Panayotou G,et al.PI3-Kinase is a clial specificity enzyme: autsregulation by an intrisinsic-serin-serine Kinase activity.Emboj,1994,13:553-533.
[12]Skolnik EY,Batzer N Li,Lee CH,et al.The function of GRB2 in linking the insulin receptor to ras signaling pathways.Science,1995,260:1953-1955.
[13]Baltensperger K,Kozma LM, Chemrniack AD,et al.Binding of the ras activator son of sevenless to insulin receptor substrate of signaling complexes.Science, 1993,260:1950-1952.
[14]Cusi K,Maezon K,Vsman A,et al.Insulin resistance differentially affects the PI3-kinase and MAPA kinase mediated signaling in human muscle.J Chin Inverse,2000,105:311-320.
[15]Tanti JE,Gremeaux T,Van Nbberghen E,et al.Serine/Threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling.J Chem,1994, 269:6051-6057.
[16]Dhand RI,Hiles G,Panayotou S,et al. PI3-kinase is a dual specificity enzyme:autoregulation by an intrinasic protein-serine kinase activity.EMBO,1994, 13:522-532.
[17]Strack V,Hennige AM,krutzfeldt J,et al.Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C is forms βand O.Diabetologia,2000,43:443-449.
[18]Nakajima K,Yamauch K,Shigematsu S,et al.Selective attenuation of metabolic branch of insulin down-signaling by high glucose in a hepatoma cell line,HepGz cells.J Biol Chem,2000,275:20990-20886.
[19]Kelly DE,Madarino LJ.Fuel selection in human skeletal muscle in insulin resistance:a reexamination.Diasetes,2000,49:677-683.
[20]Venble CL,Frerert EU,Kim YB,et al.Overexpression of protein-tyrosine Phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinos;tide3-Kinase activity without altering glucose transport or Akt/protein Kinase B activation.J Biol Chem,2000,275; 18318-18326.
[21]Nikoulina SE,Ciarald TP,Madaliars,et al.Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.Diabetes,2000, 49:263-271.
[22]Hube F,Hauner H.The two tumor necrosis factor receptor mediate opposite effects on differentiation and glucose metabolism in human adipocyte in primary culture. Endocrinology,2000,141:2582-2588.
[23]刘景生。细胞信息与调控。北京：北京医科大学、中国协和医科大学联合出 版社,1998.
[24]Laakso M,Malkk,kekalainen P,et al.Insulin receptor Substrate-1 variants in non-insulin-dependent diabetes.J Chin Invest,1994,94:1141-1146.
[25]Ima Y,Fusco A,Suzuk Y et al. Variant sequrnces of insulin receptor substrate-1 in patients with noninsulin dependent diabetes mellitus.J Chin Endocrinol Metab,1994,79:1655-1658.
[26]Whitehead JP,Humphreys P,Krook A,et al.Molecular scanning of the insulin receptor Substrate-1 gene in subjects with severe insulin resistance.Diabetes, 1998,47:837-839.
[27]Almind K,Bjrback C,Vestergaard H,et al.Aminoacid Polymorphism of insulin receptor substrate-1 non-insulin dependence mellitus.The Lanct,1993,342; 828.
[28]Hager J,Zoual H,Velho G,et al.Insulin receptor Substrate (IRS-1) gene polymorphisim in French NIDDM families.The Lancet,1993,342:1430.
[29]Ura S,Arald EI,Shirotan T.Insulin Variation of the insulin receptor substrate-1 (IRS-1)gene in Japanese patients with non-insulin-dependent diabetes mellitus.15th International Diabetes Federaqtion Congress,1994:198.
[30]Mor H,Hashiramoto M,Kishimoto Metal.Genetic analysis of IRS-1 gene in Japanese type 2 diabetes.15th International Diabetes Federaqtion Congress,1994:198.
[31]Chuang LM,Lai CS,Yeh JI et al.No association between the insulin receptor substrate-1 gene and NIDDM in the Taiwanese population.Diabetes Care,1996, 19:446-44.
[32]曾卫民、彭军、万恂恂,等。中国人工型糖尿病患者胰岛素受体底物-1基因变异的研究。中国糖尿病组织,2000,8：75-77.
[33]方启晨、项坤三、陆惠娟、等。胰岛素受体底物(IRS-1)基因Gly972Arg突变与中国人糖尿病的相关性。中国糖尿病杂志,2000,8：327-329.
[34]王国英、洪天配、张路等。胰岛素受体底物基因Gly972Arg多态性与2型糖尿病不相关。中国糖尿病杂志,2002,10：265-267.
[35]Carvalho E、Jansson PA、Axelsen M,et al.Low cellular IRS-1 gene and protein expression predict insulin resistance and NIDDM.FASEBJ,1999,13:2173-2178.
[36]Sun XJ、Crimmins DL、Myers MG Jr,et al. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1.Mol Cell Biol,1993,13:7418.
[37]Kido Y、Burks DJ、Whthers DJ,et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor IRS-1,and IRS-2.Diabetes.2001,50:1134-1142.
[38]Ducluzeau PH、Perretti N、Laville M,et al. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue.Diabetes,2001,50:1134-1142.
[39]Goody CLJ,Giorgino F,Sherman LA.et al.Insulin receptor phosphorylation,insulin receptor substrate 1 phosphorylation and phosphatidylinositol 3-Kinase activity are decreased in intake skeletal muscle strips from obese subjects.Clin Invest, 1995:2195-2204.
[40]Clausen To,Hansen T,Rjorback C,et al.Insulin resistance:interaction between obesity and a common variant of insulin receptor substrate-1.Lancet,1995, 346:397-402.
[41]Campaghs F,D Andrea MP,Baroni MG,et al.Genetic determinants of dyal:pidemia associated with the insulin resistance syndrome(IRS-1).Atherosclerosis,1997,135:97.
[42]Zhang Y、Wat N、Stratton IM,et al.UKPD19:hetenogeneity in NIDDM:separate contributions of IRS-1 and beta3-adrenergic-receptor mutation to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diavetologia,1996,39:1505-1511.
[43]Baron MG、D Andrea MP、Montal A,et al.A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease.Arteriosder Thromb Vasc Biol,1999:19:2975-2980.
[44]Boden G、Chen X、Ruiz J, et al.Meohanisms of fatty acid-induced inhibition of glucose uptake.J Chin Inverse,1994,93:2438-2446.
[45]Han DH、Hansen PA、Host HH, et al.Insulin resistance of muscle glucose transport in rats fed in rats fed a high-fat diet.Diabetes,1997,46:1761-1767.
[46]Boden GRole of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes,1997,46:3-10.
[47]Borkman M、Storeline LH、Pan DA, et al.The relationship between insulin sensitivity and fatty acid composition of skeletal muscle phospholipids.N Engl J Med,1993,328:238-244.
[48]Ashamed F、Cosignee RV、Goldsten B.Increased abundance of the receptor type protein-tyro sine phosphatase LAR aclounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects.J Chin Invese,1995,95:2806-2812.
[49]Guo X, Cheng S, Taylor KD, et al. Hypertension genes are genetic markers for insulin sensitivity and resistance [J]. Hypertension,2005,45:7992803.
[50]臧贵明,杨哗,石湘芸,等.高血压病患者血浆胰岛素原和真胰岛素水平及雷米普利干预的影响[J].中华内科杂志,2002,41：1172119.
[51]Mather K,Anderson TJ,Verma S.Insulin Action in the Vasculature;Physiology and Pathophysiology J Vasc Res 2001,38(5)415-422.
[52]Hsueh WA,Quinones MJ.Role of Endothelial Dysfunctioon in Insulin Resistance.Am J Cardiol.2003,92(4A):10J-17J
[53]Shinozaki K,Ayajiki K,Nishio Y,Sugaya T,Kashiwagi A,Okamura T (2004) Evidence for a causal role of the reninangiotensin system in vascular dysfunction associated with insulin resistance.Hypertension 43:255-262.
[54]Busse R&Fleming I.Regulation and functional consequences of endothelial nitric oxide formation.Annals of Medicine 1995;27(3):331-340.
[55]Potenza MA,Marasciulo FL,Chieppa DM et al.Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.American Journal of Physiology.Heart and Circulatory Physiology 2005;289(2):H813-H822。
[56]Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation.2000; 102:2165-2168.
[57]Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M,Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa)rats. JClin Invest.1999; 104:447-457.
[58]Juan CC,Shen YW,Chien Y,Lin YJ,Chang SF,Ho LT(2004)Insulin infusion induces endothelin-1-dependent hypertension in rats.Am J Physiol Endocrinol Metab 287:E948-E954.
[59]Behr-Roussel D,Oudot A,Caisey S,Coz OL,Gorny D,Bernabe J,Wayman C,Alexandre L,Giuliano FA(2008)Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance.Eur Urol53:1272-1281.
[60]Hsueh WA,Quinones MJ.Role of endothelial dysfuction in insulin resistance.Am J.Cardiol.2003,92(4A):10J-17J
[61]Jiang J,Tran L,Vasudevan H,Xia Z,Yuen VQMcNeill JH(2007)Endothelin-l blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat.Can J Physiol Pharmacol 85:422-499.
[62]Francesco P.Angela Sciacqua, Raffaele (2009)Maio.Endothelial dysfunction, ADMA and insulin resistance in essential hypertension.International J of Cardiology., 104:447-457.
[63]Katakam PV,Tulbert CD,Snipes JA,et al.Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species.Am J Physiol Heart Circ Physiol.2005,288(2):H854-H860.
[64]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism.Diabetes 2005;54(6):1615-1625.
[65]Nishikawa T,Edelstein D,Du XL et al.Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.Nature 2000;404 (6779):787-790.
[2]Hsueh WA,Quinones MJ.Role of Endothelial Dysfunctioon in Insulin Resistance.Am J Cardiol.2003,92(4A):10J-17J
[3]Cai H,Harrison DG.Endothelial Dysfunction in Cardiovascualr Diseases:The Role of Oxidant Stress.Circ Res,2000,87(10):840-844.
[4]Suwaidi JA,Hamasaki S,Higano S,et al.Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.Circulation,2000,101:948-954.
[5]Laakso M.Insulin resistance and cardiovascular disease.Br J Diabetes Vase Dis.2002,2(suppl 1):S9-S11.
[6]Reaven GM.Role of insulin resistance in human disease.Diabetes.1988, 37:1598-1607
[7]Baron AD.Insulin resistance and vascular function.Journal of Diabetes and Its Complications.2002,(16):92-102.
[8]Abe H,Yamada N,Kamata K,et al.Hypertension,hypertriglyceridemia,and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1.J Chin Invest,1998;101(8):1784-1788.
[9]Baron AD.Vascular Reactivity.Am J Cardiol.1999,84(1A):25J-27J
[10]Jiang ZY,Lin Y-W,Clemont A,et al.Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker(fa/fa)rats.J Chin Invest.1999, 104(4):447-457.
[11]Katakam PV,Tulbert CD,Snipes JA,et al.Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species.Am J Physiol Heart Circ Physiol.2005,288(2):H854-H860.
[12]Myers MG,White MF.The new elements of insulin signaling.Insulin receptor substrate-1 and proteins with SH2 domain.Diebetes,1993,42:643-650.
[13]Koch CA,Anderson D,Moran MF,et al.Sh2 and Sh3 domains:elements that control interactions of cytoplasmic signaling proteins.Science,1991,252:668-674.
[14]Cusi K,Maezon K,Vsman A,et al.Insulin resistance differentially affects the PI3-kinase and MAPA kinase mediated signaling in human muscle.J Chin Inverse,2000,105:311-320.
[15]Araki E,Lipes MA,Patti ME,et al.Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene.Nature,1994:372(6502):186-190.
[16]Tamemoto H,Kadowaki T,Tove K,et al.Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1.Nature,1994;372(6502):182-186
[17]Kido Y,Burks DJ,Withers D.et al.Tissue-specific insulin resistance in mice with mutation in the insulin receptor, IRS-1,and IRS-2.J Clin Invest,2000; 105:199-205.
[18]Shirakami A,Toyonaga T,Tsuruzoe K,et al.Heterozygous knockout of the IRS-1 gene in mice enhances obesity-linked insulin resistance:a possible model for the development of type 2 diabetes.J Endocrinol,2002; 174(2):309-319.
[19]Baroni MG,Leonetti F,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene is associated with insulin resistance in "uncomplicated"obese subjects evaluated by hyperinsulinemic-euglycemic clamp.J Endocrinol Invest,2004; 27(8):754-759.
[20]Baroni MG,Arca M,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene,body fat distribution and insulin-resistance.Diabetologia,2001; 44(3):367-372.
[21]Abe H,Yamada N,Kamata K,et al.Hypertension,hypertriglyceridemia,and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1.J Chin Invest,1998;101(8):1784-1788.
[22]Sloniger JA,Saengsirisuwan V,Diehl CJ,et al.Defective insulin signaling in skeletal muscle of the hypertensive TG (mREN2) 27 rat.Am J Physiol Endocrinol Metab,2005,288 (6):E1074-1081.
[23]Perticone F,Sciacqua A,Sconzzafava A,et al.Impaired endothelial function in never-treated hypertensivve subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene.J Chin Endocrinol Metab,2004;89(7):3606-3609.
[24]Federci M,Pandolfi A,De Filippis EA,et al.G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells.Circulation,2004;109(3):399-405.
[25]Sugita H.Fujimoto M,Yasukawa T,et al.Inducible nitric-oxide synthase and NO donor induce insulin receptor subtrate-1 degradation in skeletal muscle cells.J Biol Chem,2005;280(14):14203-14211.
[26]McGettrick AJ,Feener EP,Kahn CR.Human insulin receptor substrate-1 (IRS-1 polymorphism G972R causes IRS-1 to associated with the insulin receptor and inhibit receptor autophosphorylation.J Biol Chem,2005;280(8): 6441-6446.
[27]Celermajer DS,Sorenson K, Gooch VM,et al.Non-invasive detection of endothe-lial dysfunction in Children and adults at risk of atherosclerosis[J]. Lancet,1992; 340:1111-1115.
[28]Celemajer DS,Sorensen KE,Spiegelhaleter DJ,et al.Aging is associated endothelial dysfunction in healthy man years before the agerelated decline in women[J] J Am Coll Cardiol,1994;24:471-476.
[29]邓又斌,黎春蕾,朱蔚等。冷加压试验超声心动图评价高血压患者的冠状动脉内皮功能[J].中国超声医学杂志,2000；16(6)：423-425.
[l]Cherry PD,Furchgott RF,Zawadzki JV,et al.Role of endothelial cells in relaxation of isolated arteries by bradykinin[J].Proc Natl Acad Sci USA,1982;79:2106-2110.
[2]Uedas,Matsuoka H,Miyazaki H,et al.Tetrahydrobiopterin restores endothelial function in long-term smokes[J]. J Am Coll Cardiol,2000;35 (1):71-75.
[3]李妍妍,徐标。一氧化氮与心血管疾病研究进展[J]。国外医学内科学分册,2002：29(10)：426-429.
[4]Salemo JC,Harris DE,Irizarry K, et al.An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase[J].J Biol Chem,1998; 272:29769-29777.
[5]Nishida CR,de Montellano PR.Control of election transfer in mitric-oxide synthases swapping of autoinhibitory elements among nitric-oxide synthase isoforms[J].J Biol Chem,2001;276(23):20116-20124.
[6]Teubl M,Groschner K,Kohuwein SD,et al.Na+/Ca2+ exchange facilitates Ca2+-dependent activation of endothelial nitric-oxide synthase[J].J Biol Chem, 1999;274(41):29529-29535.
[7]Buga GM,Gold ME,Fukuto JM,et al.Shear stress induced release of nitric oxide from endothelial cells trown on beads[J].Hypertens,1991;17:187-193.
[8]Rai JL,Nitric oxide and the kidney[J].Circulation,1993;87:26-29.
[9]Garcia NH,Stoos BA,Carretero OA,Garvin JL.Mechanism of the nitric oxide induced blockade of collecting duct water permeability [J]. Hypertens,1996; 270:c794-802.
[10]Granger J,Novak J,Schnackenberg C,et al.Role of renal nerves in mediationg the hypertensive effects of nitric oxide synthesis inhibitioon[J].Hypertens,1996;27 (3pt2):613-617.
[11]周泉生、阮长耿。一氧化氮及其合成酶异常与疾病[J].生理学进展,1995：26：169-171.
[12]Helmut O,Basel B,Gincer H,et al.Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans[J].Circulation,1997; 96:3287-3293.
[13]Lushcher TF.Imbalance of endothelium derived relaxing and contracting factors:A new concept in hypertensioon[J].Am J Hypertens,1990;3:317.
[14]Schiffrin EL.Potential in hypertensioon and vascular hypertrophy[J].Hypertens, 1990;25:1135-43.
[15]Amir L,John CB,Stuart TH,et al.Long-term L-arginine supple-mentation improves small vessel coronary endothelial function in humans[J].Circulation, 1998;97:2123.
[16]John M.Role of angiotensin-convention enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease [J].Am J Med,1998;105(A):405.
[17]Schiffrin EL. Vascular endothelin in hypertension [J]. Vasc Pharmacol,2005, 43 (1):19229.
[18]Johnson FK, Johnson RA, Peyton KJ, et al. Arginase inhibition restores arterio2 lar endothelial function in Dahl ratswith salt2induced hypertension [J]. Am J Physiol Regul Integr Comp Physiol,2005,288 (4):R105721062.
[19]RekhviashviliA, Tsinamdzgvrishvili B, ChkhetiaM, et al. The relationship between endothelial dysfunction and 242hour blood p ressure rhythm in patients with arterial hypertension[J]. GeorgianMed News,2008,155:13217.
[20]KlingbeilAU, John S, SchneiderMP, et al. Effect of AT1 recep tor blockade on endothelial function in essential hypertension [J]. Am J Hypertens,2003,16(2) 1232128.
[21]NitenbergA, Chemla D,Antony I. Ep icardial coronary artery constriction to cold pressor test is p redictive of cardiovascular events in hypertensive patients with angiographically normal coronary arteries and without othermajor coronary risk factor [J]. Atherosclerosis,2004,173 (1):1152123.
[22]L i LJ, Yu CM, Geng SR, et al. Endothelial dysfunction in young normotensive subjectswith a family history of essential hypertension [J]. Xi'anMed Univ,2002,14 (1):81285.
[23]Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients [J]. Circulation,2001,104 (2):1912196.
[24]ModenaMG,Bonetti L, Copp i F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women [J]. J Am Coll Cardiol,2002,40 (3):5052510.
[25]VinodMAA. Cardiovascular effects of asymmetric dimethylarginine [J]. Circu2 lation,2004,109 (25):327.
[26]TousoulisD,Antoniades C, Stefanadis C. Evaluating endothelial function in humans:a guide to invasive and noninvasive techniques [J]. Heart,2005,91 (4): 5532-5558.
[27]Shinozaki K,Ayajiki K,Nishio Y,et al.Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance.Hypertension,2004,43(2):255-262.
[28]Sowers JR.Insulin resistance and hypertension.Am J Physiol Heart Circ Physiol 2004,286(5):H1597-1602.
[29]李卫萍,孙明,周宏研,等.原发性高血压病患者血管内皮功能失调与活性氧的关系及阿托伐他汀治疗的影响[J].中国现代医学杂志,2005,15(7)1096-1103.
[30]Forman HJ,Torres M,Fukuto JlRedox signaling[J]lMol Cell Biochem,2002, 234-235(1-2):49-62
[31]Campese VM, Shaohua Y, Huiquin Z. Oxidative st ress.mediates angiotensin Ⅱ2dependent stimulation of sympathetic nerve activity. Hypertension,2005,46 (3):533
[32]Madamanchi NR,Vendrov A,Runge MS1Oxidative stress and vascular dis2 ease[J]lArterioscler Thromb Vase Biol,2005,25 (1):29-38
[33]Fernndez-Real JM,Ricart Wl Insulin resistance and chronic cardiovas2 cular inflammatory syndrome[J]Endocrine Reviews,2003,24 (3):27823011
[34]Yuan,M.,Konstantopoulos,N.,Lee,J.,Hansen,L,Li,Z.W.,Karin,M.,and Shoelson,S. E.,Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta.Science,293,1673-1677(2001).
[35]Lautenberger JA, Stephens JC, O'Brien SJ, et al. Significant admixture linkage disequilibrium across30 cM around the FYlocus in African Americans. AmJ Hum Genet.2000.66(3):969-978
[36]Araki E,Sun XJ,Haag BL 3rd,et al.Human skeletal muscle insulin receptor substrate-1.Characterization of the Cdna,gene,and chromosomal localization. Diabetes,1993;42(7):1041-1054.
[37]Almind K,Bjorbaed C,Vestergaard H,et al.Amninoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus[J].Lancet,1993, 34298875:828-832.
[38]Almind K,Inoue G,Pedersen O,et al.A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling.Evidence from transfection studies,1996;97:2569-2575.
[39]Federiei M, Pandolfi A, DeFilippis EA, et al.G972RIRS-1 variarnt impairs insulin regulation of endothelial nitrie oxide synthase in cultured human endothelial cells[J].Circulation.2004,109(3):399-405
[40]Araki E, Lipes MA, Patti ME, et al.Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene [J].Nature.1994,372(6502):186-190
[41]Tamemoto H, Kadowaki T, Tobe K, et al.Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1[J]. Nature.1994,372(6502),182-186.
[42]Kido Y,Burks DJ,Withers D,et al.Tissue-specific insulin resistance in mice with mutations in the insulin receptor,IRS-1,and IRS-2.J Chin Invest,2000; 105:199-205.
[43]Shirkami A,Toyonaga T,Tsuruzoe K,et al.Heterozygous knockout of the IRS-1 gene in mice enhances obesity-linked insulin resistance:a possible model for the development of type 2 diabetes.J Endocrinol,2002;174(2):309-319.
[44]Baroni MG,Leonetti F,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene is associated with insulin resistance in "uncomplicated" obese subjects evaluated by hyperinsulinemic-euglycemic clamp.J Endocrinol Invest,2004;27(8):754-759.
[45]Baroni MG,Arca M,Sentinelli F,et al.The G972R variant of the insulin receptor substrate-1 (IRS-1)gene,body fat distribution and insulin-resistance.Diabetologia,2001;44(3):367-372.
[46]Abe H,Yamada N,Kamata K,et al.Hypertension,hypertriglyceridemia,and impaired endothelium-dependent vascular relaxationin mice lacking insulin receptor substrate-1.J Chin Invest,1998;101(8):1784-1788.
[47]Francesco P,Angela Sciacqua,Angela S,et al.Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene.J.Clin.Endocrinol.Metab,2004;89:3606-3609.
[48]Baroni MG,D'Andrea MP,Montali A,Pannitteri G,Barilla F,Campagna F, Mazzei E,Lovari S,Sceeareccia F,Campa PP,Ricci G,Pazzilli P,Urbinati G,Arca M 1999 A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease.Arterioscler Thromb Vasc Biol 19:2975-2980.
[49]Ossei-Gerning N,Mansfield MW,Stickland MH,Grant PJ.Insulin receptor substrate-1 gene polymorphism and cardiovascular risk in non-insulin dependent diabetes mellitus and patients undergoing coronary angiography.Clin Lab Haema tol.1997 Jun; 19(2) 123-8.
[50]Massimo Federici,Assunta Pandolfi,Elena Anna De Filippis et al.G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells.Circulation 2004;109;399-405.
[51]Zeng G,Quon MJ.Insulin-stimulated production of nitric oxide by wortmannin.Direct measurement in vascular endothelial cells.J Chin Invest,1996,98:894-989.
[52]Potenza MA,Marasciulo FL,Chieppa DM et al.Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.American Journal of Physiology.Heart and Circulatory Physiology 2005;289(2):H813-H822。
[53]Formoso G, Chen H,Kim JA,Montagnani M,Consoli A,Quon MJ.Dehydro-epiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin-1 via distinct phosphatidylinositol 3-kinase-and mitogen-activated protein kinase-dependent pathways in vascular endothelium.Mol Endocrinol,2006,20:1153-1163.
[54]Potenza MA,Marasciulo FL,Tarquinio M,Quon MJ,Montagnani M,Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.Diabetes,2006,55:3594-3603.
[55]Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M,Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa)rats. J Clin Invest.1999; 104:447-457.
[56]Cusi K,Maezono K,Osman A,Pendergrass M,Patti ME,Pratipanawatr T,DeFronzo RA,Kahn CR,Mandarino LJ.Insulin resistance differentially affects the PI 3-kinase and MAP-kinase-mediated signaling muscle.J Chin Invest,2000,105:311-320.
[57]Juan CC,Shen YW,Chien Y,Lin YJ,Chang SF,Ho LT(2004)Insulin infusion induces endothelin-1-dependent hypertension in rats.Am J Physiol Endocrinol Metab 287:E948-E954.
[58]Shinozaki K,Ayajiki K,Nishio Y,Sugaya T,Kashiwagi A,Okamura T (2004) Evidence for a causal role of the reninangiotensin system in vascular dysfunction associated with insulin resistance.Hypertension 43:255-262.
[59]Behr-Roussel D,Oudot A,Caisey S,Coz OL,Gorny D,Bernabe J,Wayman C,Alexandre L,Giuliano FA(2008)Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance.Eur Urol53: 1272-1281.
[60]Hsueh WA,Quinones MJ.Role of endothelial dysfuction in insulin resistance.Am J.Cardiol.2003,92(4A):10J-17J
[61]Francesco P.Angela Sciacqua, Raffaele (2009)Maio.Endothelial dysfunction, ADMA and insulin resistance in essential hypertension.International J of Cardiology., 104:447-457.
[62]Arcaro QCretti A,Balzano S,Lechi A,Muggeo M,Bonora E,Bonadonna RC.Insulin causes endothelial dysfunction in humans:sites and mechanisms.Circula-tion,2002,105:576-582.
[63]邓又斌,黎春蕾,朱蔚等。冷加压试验超声心动图评价高血压患者的冠状动脉内皮功能[J].中国超声医学杂志,2000；16(6)：423-425.
[1]Yusuf S,Sleight P,Pogue J,et al.Effects of an angiotensin-converting-enzyme inhibitor,ramipril,on cardiovascular events in high-risk patients:the heart outcomes prevention evaluation study investigations[J],N Engl Med,2000,342(3):145-153.
[2]Yoshida J, Yamamoto K,Mano T, et all AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure[J]1 Hypertension,2004,43 (3):686-691
[3]Ghiadoni L,Magagna A,Versari D, et all Different effect of antihyperten-sive drugs on conduit artery endothelial function[J]1 Hypertension,2003,41 (6):1281-1286.
[4]Higashi Y,Oshima T,Sasaki S,et al.Angiotensin-converting enzyme inhitibition,but not calcium angagomism,improves a response of the renal vasculature to L-arginine in patients with essential hypertensive[J],Hypertension,1998,32:16-24.
[5]O' Driscoll G,Green D,Maiorana A,et al.Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus[J].JACC,1999,33(6):1506-1511.
[6]Shinozaki K,Ayajiki K,Nishio Y,et al.Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance.Hypertension,2004,43(2):255-262.
[7]Nyby MD,Abedi K,Smutko V,Eslami P,Tuck ML(2007)Vascular Angiotensin type 1 receptor expression is associated with vasular dysfunction,oxidative stress and inflammation in fructose-fed rats.Hypertens Res 30:451-457.
[8]Kamide K,Rakugi H,Higaki J,Okamura A,Nagia M,Moriguchi K,Ohishi M,Satoh N,Tuck ML,Ogihara (2002) The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats.Am J Hypertens 15:66-71.
[9]Uchida T,Okumura K,Ito T,Kamiya H,Nishimoto Y,Yamada M,Tomida T,Matsui H,Hayakawa T(2002)Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats.Clin Exp Pharmacol Physiol 29:381-385.
[10]Blanquart C, Barbier O, Fruchart JC, et al. Peroxisome p roliferator-activated recep tors:regulation of transcrip tional activities and roles in inflammation[J]. J Steroid BiochemMolBiol,2003,85 (225):2672273.
[11]RicoteM, Li AC, Willson TM, et al. The peroxisome p roliferator-activated recep tor2gamma is a negative regulator ofmacrophage activation[J]. Nature,1998, 391(6662):79282.
[12]Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR2gamma ligands to inhibit the ep ithelial inflammatory response [J]. J Clin Invest,1999,104 (4):3832389.
[13]Von Knethen AA, Brune B. Delayed activation of PPARgamma by LPS and IFN2gamma attenuates the oxidative burst in macrophages [J]. FASEB J,2001,15 (2):5352544.
[1]Tsuj Y,Kaburagi Y,Teranchi Y,et al.Subcellular Localization of insulin receptor Substrate Family proteins associated with phosphatidylinositol 3-kinase activity and alteration in lipolysis in primary mouse adipocytes from IRS-1 null mice[J].Diabetes,2001,50:1455-1463.
[2]Myers MG Jr,Grammer TC,Blooks J,et al/THE Plecksrin homology domain in IRS-1 sensitizes insulin signling.J Biol Chem,1995-270:11715-11718.
[3]Sun XJ,Rothenberg P,Kabncr,et al.Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein.Nature,1991,352:73-77.
[4]Araki E, Sun XJ,Hang BL,et al.Human skeletal muscle insulin receptor substrate-1,characterization of the CDNA.gene and chromosomal localization. Diabetes,1993,42:1041-1054.
[5]Nishiyama M,Wands JR.Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma.Biochem.Biophys. Res.Commun,1992,183:280-285.
[6]Myers MG,White MF.The new elements of insulin signaling.Insulin receptor substrate-1 and proteins with SH2 domain.Diebetes,1993,42:643-650.
[7]Koch CA,Anderson D,Moran MF,et al.Sh2 and Sh3 domains:elements that control interactions of cytoplasmic signaling proteins.Science,1991,252:668-674.
[8]Foll F,Saad MJ,Backer JM,et al.Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus.J Chin Inverse,1993,92:1787-1794.
[9]Lowenstein EJ,Daly RJ,Batzer AG,et al.The SH2 and SH3 domain-containing GRB2 links receptor tyrosine Kinases to ras signaling.Cell,1992,70:431-442.
[10]White MF.The insulin signaling system and the IRS proteins.Diabetoligia,1997, 40:12-17.
[11]Dhand r,Hiles I,Panayotou G,et al.PI3-Kinase is a clial specificity enzyme: autsregulation by an intrisinsic-serin-serine Kinase activity.Emboj,1994,13:553-533.
[12]Skolnik EY,Batzer N Li,Lee CH,et al.The function of GRB2 in linking the insulin receptor to ras signaling pathways.Science,1995,260:1953-1955.
[13]Baltensperger K,Kozma LM, Chemrniack AD,et al.Binding of the ras activator son of sevenless to insulin receptor substrate of signaling complexes.Science, 1993,260:1950-1952.
[14]Cusi K,Maezon K,Vsman A,et al.Insulin resistance differentially affects the PI3-kinase and MAPA kinase mediated signaling in human muscle.J Chin Inverse,2000,105:311-320.
[15]Tanti JE,Gremeaux T,Van Nbberghen E,et al.Serine/Threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling.J Chem,1994, 269:6051-6057.
[16]Dhand RI,Hiles G,Panayotou S,et al. PI3-kinase is a dual specificity enzyme:autoregulation by an intrinasic protein-serine kinase activity.EMBO,1994, 13:522-532.
[17]Strack V,Hennige AM,krutzfeldt J,et al.Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C is forms βand O.Diabetologia,2000,43:443-449.
[18]Nakajima K,Yamauch K,Shigematsu S,et al.Selective attenuation of metabolic branch of insulin down-signaling by high glucose in a hepatoma cell line,HepGz cells.J Biol Chem,2000,275:20990-20886.
[19]Kelly DE,Madarino LJ.Fuel selection in human skeletal muscle in insulin resistance:a reexamination.Diasetes,2000,49:677-683.
[20]Venble CL,Frerert EU,Kim YB,et al.Overexpression of protein-tyrosine Phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinos;tide3-Kinase activity without altering glucose transport or Akt/protein Kinase B activation.J Biol Chem,2000,275; 18318-18326.
[21]Nikoulina SE,Ciarald TP,Madaliars,et al.Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.Diabetes,2000, 49:263-271.
[22]Hube F,Hauner H.The two tumor necrosis factor receptor mediate opposite effects on differentiation and glucose metabolism in human adipocyte in primary culture. Endocrinology,2000,141:2582-2588.
[23]刘景生。细胞信息与调控。北京：北京医科大学、中国协和医科大学联合出 版社,1998.
[24]Laakso M,Malkk,kekalainen P,et al.Insulin receptor Substrate-1 variants in non-insulin-dependent diabetes.J Chin Invest,1994,94:1141-1146.
[25]Ima Y,Fusco A,Suzuk Y et al. Variant sequrnces of insulin receptor substrate-1 in patients with noninsulin dependent diabetes mellitus.J Chin Endocrinol Metab,1994,79:1655-1658.
[26]Whitehead JP,Humphreys P,Krook A,et al.Molecular scanning of the insulin receptor Substrate-1 gene in subjects with severe insulin resistance.Diabetes, 1998,47:837-839.
[27]Almind K,Bjrback C,Vestergaard H,et al.Aminoacid Polymorphism of insulin receptor substrate-1 non-insulin dependence mellitus.The Lanct,1993,342; 828.
[28]Hager J,Zoual H,Velho G,et al.Insulin receptor Substrate (IRS-1) gene polymorphisim in French NIDDM families.The Lancet,1993,342:1430.
[29]Ura S,Arald EI,Shirotan T.Insulin Variation of the insulin receptor substrate-1 (IRS-1)gene in Japanese patients with non-insulin-dependent diabetes mellitus.15th International Diabetes Federaqtion Congress,1994:198.
[30]Mor H,Hashiramoto M,Kishimoto Metal.Genetic analysis of IRS-1 gene in Japanese type 2 diabetes.15th International Diabetes Federaqtion Congress,1994:198.
[31]Chuang LM,Lai CS,Yeh JI et al.No association between the insulin receptor substrate-1 gene and NIDDM in the Taiwanese population.Diabetes Care,1996, 19:446-44.
[32]曾卫民、彭军、万恂恂,等。中国人工型糖尿病患者胰岛素受体底物-1基因变异的研究。中国糖尿病组织,2000,8：75-77.
[33]方启晨、项坤三、陆惠娟、等。胰岛素受体底物(IRS-1)基因Gly972Arg突变与中国人糖尿病的相关性。中国糖尿病杂志,2000,8：327-329.
[34]王国英、洪天配、张路等。胰岛素受体底物基因Gly972Arg多态性与2型糖尿病不相关。中国糖尿病杂志,2002,10：265-267.
[35]Carvalho E、Jansson PA、Axelsen M,et al.Low cellular IRS-1 gene and protein expression predict insulin resistance and NIDDM.FASEBJ,1999,13:2173-2178.
[36]Sun XJ、Crimmins DL、Myers MG Jr,et al. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1.Mol Cell Biol,1993,13:7418.
[37]Kido Y、Burks DJ、Whthers DJ,et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor IRS-1,and IRS-2.Diabetes.2001,50:1134-1142.
[38]Ducluzeau PH、Perretti N、Laville M,et al. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue.Diabetes,2001,50:1134-1142.
[39]Goody CLJ,Giorgino F,Sherman LA.et al.Insulin receptor phosphorylation,insulin receptor substrate 1 phosphorylation and phosphatidylinositol 3-Kinase activity are decreased in intake skeletal muscle strips from obese subjects.Clin Invest, 1995:2195-2204.
[40]Clausen To,Hansen T,Rjorback C,et al.Insulin resistance:interaction between obesity and a common variant of insulin receptor substrate-1.Lancet,1995, 346:397-402.
[41]Campaghs F,D Andrea MP,Baroni MG,et al.Genetic determinants of dyal:pidemia associated with the insulin resistance syndrome(IRS-1).Atherosclerosis,1997,135:97.
[42]Zhang Y、Wat N、Stratton IM,et al.UKPD19:hetenogeneity in NIDDM:separate contributions of IRS-1 and beta3-adrenergic-receptor mutation to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diavetologia,1996,39:1505-1511.
[43]Baron MG、D Andrea MP、Montal A,et al.A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease.Arteriosder Thromb Vasc Biol,1999:19:2975-2980.
[44]Boden G、Chen X、Ruiz J, et al.Meohanisms of fatty acid-induced inhibition of glucose uptake.J Chin Inverse,1994,93:2438-2446.
[45]Han DH、Hansen PA、Host HH, et al.Insulin resistance of muscle glucose transport in rats fed in rats fed a high-fat diet.Diabetes,1997,46:1761-1767.
[46]Boden GRole of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes,1997,46:3-10.
[47]Borkman M、Storeline LH、Pan DA, et al.The relationship between insulin sensitivity and fatty acid composition of skeletal muscle phospholipids.N Engl J Med,1993,328:238-244.
[48]Ashamed F、Cosignee RV、Goldsten B.Increased abundance of the receptor type protein-tyro sine phosphatase LAR aclounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects.J Chin Invese,1995,95:2806-2812.
[49]Guo X, Cheng S, Taylor KD, et al. Hypertension genes are genetic markers for insulin sensitivity and resistance [J]. Hypertension,2005,45:7992803.
[50]臧贵明,杨哗,石湘芸,等.高血压病患者血浆胰岛素原和真胰岛素水平及雷米普利干预的影响[J].中华内科杂志,2002,41：1172119.
[51]Mather K,Anderson TJ,Verma S.Insulin Action in the Vasculature;Physiology and Pathophysiology J Vasc Res 2001,38(5)415-422.
[52]Hsueh WA,Quinones MJ.Role of Endothelial Dysfunctioon in Insulin Resistance.Am J Cardiol.2003,92(4A):10J-17J
[53]Shinozaki K,Ayajiki K,Nishio Y,Sugaya T,Kashiwagi A,Okamura T (2004) Evidence for a causal role of the reninangiotensin system in vascular dysfunction associated with insulin resistance.Hypertension 43:255-262.
[54]Busse R&Fleming I.Regulation and functional consequences of endothelial nitric oxide formation.Annals of Medicine 1995;27(3):331-340.
[55]Potenza MA,Marasciulo FL,Chieppa DM et al.Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.American Journal of Physiology.Heart and Circulatory Physiology 2005;289(2):H813-H822。
[56]Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation.2000; 102:2165-2168.
[57]Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M,Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa)rats. JClin Invest.1999; 104:447-457.
[58]Juan CC,Shen YW,Chien Y,Lin YJ,Chang SF,Ho LT(2004)Insulin infusion induces endothelin-1-dependent hypertension in rats.Am J Physiol Endocrinol Metab 287:E948-E954.
[59]Behr-Roussel D,Oudot A,Caisey S,Coz OL,Gorny D,Bernabe J,Wayman C,Alexandre L,Giuliano FA(2008)Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance.Eur Urol53:1272-1281.
[60]Hsueh WA,Quinones MJ.Role of endothelial dysfuction in insulin resistance.Am J.Cardiol.2003,92(4A):10J-17J
[61]Jiang J,Tran L,Vasudevan H,Xia Z,Yuen VQMcNeill JH(2007)Endothelin-l blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat.Can J Physiol Pharmacol 85:422-499.
[62]Francesco P.Angela Sciacqua, Raffaele (2009)Maio.Endothelial dysfunction, ADMA and insulin resistance in essential hypertension.International J of Cardiology., 104:447-457.
[63]Katakam PV,Tulbert CD,Snipes JA,et al.Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species.Am J Physiol Heart Circ Physiol.2005,288(2):H854-H860.
[64]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism.Diabetes 2005;54(6):1615-1625.
[65]Nishikawa T,Edelstein D,Du XL et al.Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.Nature 2000;404 (6779):787-790.